Effects of multiple sclerosis disease-modifying therapies on employment measures using patient-reported data.

Jing ChenBruce V TaylorLeigh BlizzardSteve Simpson YapAndrew J PalmerIngrid A F van der Mei

Published in: Journal of neurology, neurosurgery, and psychiatry (2018)

Those using the higher efficacy (category 3) DMTs, particularly fingolimod and natalizumab, reported significant increases in amount of work, work attendance and work productivity, suggesting they have important beneficial effects on work life in people with MS.

Keyphrases

multiple sclerosis
patient reported
white matter
climate change
electronic health record
big data
mental illness
mass spectrometry
data analysis
mental health
ms ms